HUTCHMED (China) Limited announced that updated analysis of the ongoing international Phase I/Ib trial of fruquintinib will be presented at the upcoming 2022 ASCO Gastrointestinal Cancers Symposium, taking place on January 20-22, 2022. The meeting will be held virtually and in person at the Moscone Center in San Francisco, California, US.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
303 GBX | +2.36% | +11.81% | +7.07% |
Apr. 05 | Hutchmed to Present New Data at US Cancer Research Conference | MT |
Apr. 05 | HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.07% | 3.14B | |
+22.98% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+12.17% | 219B | |
+6.35% | 199B | |
-9.90% | 196B | |
-8.75% | 149B | |
-5.21% | 146B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- HUTCHMED Limited Update Analysis of Ongoing International Phase I/Ib Trial of Fruquintinib